Targeted therapies for cutaneous T-cell lymphomas.

about

Primary cutaneous T-cell lymphomas: a review.Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.

P2860

Q34502896-CD945728-9515-4B81-AEC5-1FF54ACBDC06 Q34516083-28442415-5C35-4A8A-90E6-9D739F19712E

P2860

Targeted therapies for cutaneous T-cell lymphomas.

Item

http://www.wikidata.org/entity/Q38229634

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Targeted therapies for cutaneous T-cell lymphomas.

@en

type

Item

label

Targeted therapies for cutaneous T-cell lymphomas.

@en

prefLabel

Targeted therapies for cutaneous T-cell lymphomas.

@en

P1476

Targeted therapies for cutaneous T-cell lymphomas.

@en

P2093

Francis J Giles

http://www.w3.org/2001/XMLSchema#string

Jason B Kaplan

http://www.w3.org/2001/XMLSchema#string

Joan Guitart

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of lenalidomide in hematological malignancies

Hallmarks of Cancer: The Next Generation

Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

P304

481-493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474086.2014.942279

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25025372

http://www.w3.org/2001/XMLSchema#string

Targeted therapies for cutaneous T-cell lymphomas.

about

P2860

P2860

Targeted therapies for cutaneous T-cell lymphomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698